

NeuroCure Therapeutics

Overview

NeuroCure Therapeutics is an early-stage biotech company focused on developing targeted therapies for glioblastoma multiforme (GBM), one of the most aggressive brain cancers. Our proprietary NeuroBridge™ platform delivers small-molecule inhibitors across the blood-brain barrier using a novel receptor-mediated transport system. This approach addresses a critical challenge in neuro-oncology by enabling effective drug delivery to tumor sites while minimizing systemic toxicity. The platform is designed for adaptability, allowing expansion into other CNS malignancies and neurodegenerative disorders, creating a robust pipeline opportunity.

Problem

GBM accounts for nearly 50% of malignant brain tumors and carries a median survival of less than 15 months. Current treatments, including surgery, radiation, and chemotherapy, offer limited benefit due to poor drug penetration across the blood-brain barrier and rapid tumor recurrence. There is an urgent need for therapies that can effectively reach the tumor site and disrupt key survival pathways.

Solution

NeuroBridge™ enables targeted delivery of kinase inhibitors directly to GBM cells by exploiting receptor-mediated transport mechanisms. This precision approach enhances drug accumulation in tumor tissue while reducing off-target effects. By overcoming the blood-brain barrier challenge, NeuroCure offers a transformative solution for GBM and other CNS diseases.

Market

GBM affects approximately 13,000 patients annually in the United States and over 120,000 worldwide. The estimated addressable market for GBM therapies exceeds \$3 billion annually, with additional opportunities in other CNS cancers and neurodegenerative conditions pushing the potential market beyond \$10 billion. Global neuro-oncology

therapeutics are projected to grow at a CAGR of 12%, driven by unmet clinical needs and technological advancements.

Clinical Need

Current GBM treatments fail to provide durable responses, and no approved therapies effectively overcome the blood-brain barrier. NeuroBridge™ addresses this gap by enabling targeted delivery of potent inhibitors to tumor sites, improving efficacy and patient outcomes.

Competition

Existing GBM therapies include temozolomide and tumor-treating fields, which offer modest survival benefits. Emerging approaches such as CAR-T and oncolytic viruses face delivery and safety challenges. NeuroCure's differentiated platform positions it as a first-in-class solution for effective CNS drug delivery.

Team

CEO: Dr. Michael Torres, PhD (neuropharmacology, ex-Novartis). CSO: Dr. Aisha Rahman, PhD (blood-brain barrier biology, Harvard). Advisors include Dr. Emily Chen (Dana-Farber) and Dr. Raj Patel (Johns Hopkins), providing expertise in neuro-oncology and translational research.

Capital Raised & Seeking

Raised: \$1M (founders + NIH grant). Seeking: \$6M Seed Round to advance NeuroBridge™ through IND-enabling studies and initiate Phase I trials.

Use of Funds

Funds will be allocated to optimize NeuroBridge™ formulation, complete GLP toxicology, and prepare IND submission for GBM clinical trials. Additional resources will support regulatory engagement and strategic partnerships.

Timeline

18 months to IND submission.